| Members |
acceptabilityId |
| 5 |
Preferred (foundation metadata concept) |
| 5 |
Preferred (foundation metadata concept) |
| 5 (qualifier value) |
Preferred (foundation metadata concept) |
| 5 French gauge |
Preferred (foundation metadata concept) |
| 5 French gauge (qualifier value) |
Preferred (foundation metadata concept) |
| 5 IU/0.1mL |
Acceptable (foundation metadata concept) |
| 5 International Units in 0.1mL |
Preferred (foundation metadata concept) |
| 5 International Units in 0.1mL (qualifier value) |
Preferred (foundation metadata concept) |
| 5 alpha-cholest-8(9)-en-3 beta-ol |
Acceptable (foundation metadata concept) |
| 5 aza 2 desoxycytidine |
Acceptable (foundation metadata concept) |
| 5 azacytidine |
Acceptable (foundation metadata concept) |
| 5 azadeoxycytidine |
Acceptable (foundation metadata concept) |
| 5 hours |
Preferred (foundation metadata concept) |
| 5 hours (qualifier value) |
Preferred (foundation metadata concept) |
| 5 level of presenting part in relation to ischial spines |
Preferred (foundation metadata concept) |
| 5 level of presenting part in relation to ischial spines (finding) |
Preferred (foundation metadata concept) |
| 5 o'clock position |
Preferred (foundation metadata concept) |
| 5 o'clock position (qualifier value) |
Preferred (foundation metadata concept) |
| 5 o'clock position on mammogram |
Preferred (foundation metadata concept) |
| 5 o'clock position on mammogram (finding) |
Preferred (foundation metadata concept) |
| 5 times a week |
Acceptable (foundation metadata concept) |
| 5% Acetic acid |
Preferred (foundation metadata concept) |
| 5% Acetic acid (substance) |
Preferred (foundation metadata concept) |
| 5' Nucleotidase measurement |
Preferred (foundation metadata concept) |
| 5' Nucleotidase measurement (procedure) |
Preferred (foundation metadata concept) |
| 5' acylphosphoadenosine hydrolase |
Preferred (foundation metadata concept) |
| 5' acylphosphoadenosine hydrolase (substance) |
Preferred (foundation metadata concept) |
| 5'-exonuclease |
Acceptable (foundation metadata concept) |
| 5'-methylthioadenosine phosphorylase |
Preferred (foundation metadata concept) |
| 5'-methylthioadenosine phosphorylase (substance) |
Preferred (foundation metadata concept) |
| 5'-nucleotidase |
Preferred (foundation metadata concept) |
| 5'-nucleotidase (substance) |
Preferred (foundation metadata concept) |
| 5'-polynucleotidase |
Acceptable (foundation metadata concept) |
| 5,10-Methylenetetrahydrofolate reductase (FADH>2<) measurement |
Preferred (foundation metadata concept) |
| 5,10-Methylenetetrahydrofolate reductase (reduced flavin adenine dinucleotide) measurement |
Acceptable (foundation metadata concept) |
| 5,10-Methylenetetrahydrofolate reductase (reduced flavin adenine dinucleotide) measurement (procedure) |
Preferred (foundation metadata concept) |
| 5,10-Methylenetetrahydrofolate reductase deficiency |
Preferred (foundation metadata concept) |
| 5,10-Methylenetetrahydrofolate reductase deficiency (disorder) |
Preferred (foundation metadata concept) |
| 5,10-methenyltetrahydrofolate synthetase |
Acceptable (foundation metadata concept) |
| 5,10-methylenetetrahydrofolate reductase (FADH>2<) |
Preferred (foundation metadata concept) |
| 5,10-methylenetetrahydrofolate reductase (reduced flavin adenine dinucleotide) |
Acceptable (foundation metadata concept) |
| 5,10-methylenetetrahydrofolate reductase (reduced flavin adenine dinucleotide) (substance) |
Preferred (foundation metadata concept) |
| 5,10-methylenetetrahydrofolate reductase gene analysis |
Preferred (foundation metadata concept) |
| 5,10-methylenetetrahydrofolate reductase gene analysis (procedure) |
Preferred (foundation metadata concept) |
| 5,25-dihydroxy cholecalciferol |
Preferred (foundation metadata concept) |
| 5,25-dihydroxy cholecalciferol (substance) |
Preferred (foundation metadata concept) |
| 5,6-dihydrouracil |
Preferred (foundation metadata concept) |
| 5,6-dihydrouracil (substance) |
Preferred (foundation metadata concept) |
| 5,8,11,14-eicosatetraenoic acid |
Acceptable (foundation metadata concept) |
| 5,8,11-eicosatrienoic acid |
Preferred (foundation metadata concept) |
| 5,8,11-eicosatrienoic acid (substance) |
Preferred (foundation metadata concept) |
| 5-(3,4-diacetoxybut-1-ynyl)-2,2'-bithiophene deacetylase |
Preferred (foundation metadata concept) |
| 5-(3,4-diacetoxybut-1-ynyl)-2,2'-bithiophene deacetylase (substance) |
Preferred (foundation metadata concept) |
| 5-ASA |
Acceptable (foundation metadata concept) |
| 5-Aminolevulinate synthase |
Preferred (foundation metadata concept) |
| 5-Aminolevulinate synthase (substance) |
Preferred (foundation metadata concept) |
| 5-Chloro-2-methyl-4-isothiazolin-3-one and 2-methyl-4-isothiazolin-3-one Kathon (3:1 in water) |
Preferred (foundation metadata concept) |
| 5-Chloro-2-methyl-4-isothiazolin-3-one and 2-methyl-4-isothiazolin-3-one Kathon (3:1 in water) (product) |
Preferred (foundation metadata concept) |
| 5-Chloro-7-iodo-quinolinol |
Preferred (foundation metadata concept) |
| 5-Chloro-7-iodo-quinolinol |
Preferred (foundation metadata concept) |
| 5-Chloro-7-iodo-quinolinol (product) |
Preferred (foundation metadata concept) |
| 5-Chloro-7-iodo-quinolinol (substance) |
Preferred (foundation metadata concept) |
| 5-FC |
Acceptable (foundation metadata concept) |
| 5-Fluorocytosine measurement |
Acceptable (foundation metadata concept) |
| 5-HIAA - 5-Hydroxyindole acetic acid |
Acceptable (foundation metadata concept) |
| 5-HIAA - 5-Hydroxyindole acetic acid |
Acceptable (foundation metadata concept) |
| 5-HIAA - 5-Hydroxyindole acetic acid |
Acceptable (foundation metadata concept) |
| 5-HIAA quantitative, urine |
Acceptable (foundation metadata concept) |
| 5-HPETE |
Acceptable (foundation metadata concept) |
| 5-HT - 5-hydroxytryptamine |
Acceptable (foundation metadata concept) |
| 5-HT secreting neuroendocrine tumor |
Preferred (foundation metadata concept) |
| 5-HT3 receptor antagonist |
Preferred (foundation metadata concept) |
| 5-HT3 receptor antagonist |
Preferred (foundation metadata concept) |
| 5-HT3 receptor antagonist-containing product |
Preferred (foundation metadata concept) |
| 5-HT3-receptor antagonist adverse reaction |
Preferred (foundation metadata concept) |
| 5-HT3-receptor antagonist allergy |
Acceptable (foundation metadata concept) |
| 5-HT3-receptor antagonist overdose |
Preferred (foundation metadata concept) |
| 5-HT3-receptor antagonist overdose of undetermined intent |
Preferred (foundation metadata concept) |
| 5-HT3-receptor antagonist poisoning |
Preferred (foundation metadata concept) |
| 5-HT3-receptor antagonist poisoning of undetermined intent |
Preferred (foundation metadata concept) |
| 5-He |
Acceptable (foundation metadata concept) |
| 5-Hydroxy-indoleacetic acid |
Preferred (foundation metadata concept) |
| 5-Hydroxy-indoleacetic acid (substance) |
Preferred (foundation metadata concept) |
| 5-Hydroxyhexanoate measurement |
Preferred (foundation metadata concept) |
| 5-Hydroxyhexanoate measurement (procedure) |
Preferred (foundation metadata concept) |
| 5-Hydroxyindoleacetic acid |
Preferred (foundation metadata concept) |
| 5-Hydroxyindoleacetic acid (substance) |
Preferred (foundation metadata concept) |
| 5-Hydroxyindoleacetic acid measurement |
Preferred (foundation metadata concept) |
| 5-Hydroxyindoleacetic acid measurement (procedure) |
Preferred (foundation metadata concept) |
| 5-Hydroxyindoleacetic acid measurement, quantitative, urine |
Preferred (foundation metadata concept) |
| 5-Hydroxyindoleacetic acid measurement, quantitative, urine (procedure) |
Preferred (foundation metadata concept) |
| 5-Hydroxyindoleacetic acid/creatinine ratio measurement |
Preferred (foundation metadata concept) |
| 5-Hydroxyindoleacetic acid/creatinine ratio measurement (procedure) |
Preferred (foundation metadata concept) |
| 5-Hydroxytryptamine measurement |
Acceptable (foundation metadata concept) |
| 5-Hydroxytryptamine release |
Acceptable (foundation metadata concept) |
| 5-Hydroxytryptamine release measurement |
Preferred (foundation metadata concept) |
| 5-Hydroxytryptamine release measurement (procedure) |
Preferred (foundation metadata concept) |
| 5-Hydroxytryptamine uptake |
Acceptable (foundation metadata concept) |
| 5-Hydroxytryptamine uptake measurement |
Preferred (foundation metadata concept) |
| 5-Hydroxytryptamine uptake measurement (procedure) |
Preferred (foundation metadata concept) |
| 5-Hydroxytryptamine-3-receptor antagonist adverse reaction |
Acceptable (foundation metadata concept) |
FHIR